NASDAQ:GLSI

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

Greenwich LifeSciences logo
$13.76 -1.18 (-7.90%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$13.68 -0.08 (-0.58%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Greenwich LifeSciences Stock (NASDAQ:GLSI)

Advanced

Key Stats

Today's Range
$13.38
▼
$15.04
50-Day Range
$13.76
▼
$19.48
52-Week Range
$7.78
▼
$34.10
Volume
153,544 shs
Average Volume
130,920 shs
Market Capitalization
$202.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.00
Consensus Rating
Hold

Company Overview

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment.

GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.

The company is based in Stafford, Texas. Its founder and chief executive officer is Snehal Patel.

AI Generated. May Contain Errors.

Greenwich LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

GLSI MarketRank™: 
1.53096636412 of 5 stars

Greenwich LifeSciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 765th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Greenwich LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Greenwich LifeSciences has a consensus price target of $69.00, representing about 401.5% upside from its current price of $13.76.

  • Amount of Analyst Coverage

    Greenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Greenwich LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Greenwich LifeSciences are expected to grow in the coming year, from ($1.29) to ($1.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Greenwich LifeSciences is -8.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Greenwich LifeSciences is -8.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Greenwich LifeSciences has a P/B Ratio of 458.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    22.07% of the float of Greenwich LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Greenwich LifeSciences has a short interest ratio ("days to cover") of 12.51, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Greenwich LifeSciences has recently increased by 1.66%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Greenwich LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Greenwich LifeSciences does not have a long track record of dividend growth.

  • News Sentiment

    Greenwich LifeSciences has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Greenwich LifeSciences this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Greenwich LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    51.28% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    4.16% of the stock of Greenwich LifeSciences is held by institutions.

  • Read more about Greenwich LifeSciences' insider trading history.
Receive GLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GLSI Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
See More Headlines

GLSI Stock Analysis - Frequently Asked Questions

Greenwich LifeSciences' stock was trading at $21.01 at the start of the year. Since then, GLSI stock has decreased by 34.5% and is now trading at $13.76.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) posted its quarterly earnings results on Monday, November, 16th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.07.

Greenwich LifeSciences (GLSI) raised $8 million in an initial public offering on Friday, September 25th 2020. The company issued 1,260,870 shares at $5.75-$6.75 per share. Aegis Capital served as the underwriter for the IPO.

Greenwich LifeSciences' top institutional investors include State Street Corp (1.09%), Goldman Sachs Group Inc. (0.39%) and Russell Investments Group Ltd. (0.01%). Insiders that own company stock include Snehal Patel and Jaye Thompson.
View institutional ownership trends
.

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Palantir Technologies (PLTR), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), FuelCell Energy (FCEL), Pfizer (PFE) and QuantumScape (QS).

Company Calendar

Today
11/16/2026
Last Earnings
11/16/2026
Next Earnings (Estimated)
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GLSI
CIK
1799788
Fax
N/A
Employees
13
Year Founded
2006

Price Target and Rating

High Price Target
$69.00
Low Price Target
$69.00
Potential Upside/Downside
+401.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.36 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-793.81%
Return on Assets
-295.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.54
Quick Ratio
1.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.03 per share
Price / Book
458.67

Miscellaneous

Outstanding Shares
14,680,000
Free Float
7,151,000
Market Cap
$202.00 million
Optionable
Not Optionable
Beta
1.57

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:GLSI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners